Remicade approved for psoriatic arthritis
Centocor announced that the FDA had expanded its approval for Remicade to include psoriatic arthritis. The approval is for inhibiting the progression of structural damage along with improved physical function. About a million people in the U.S. suffer from psoriatic arthritis.
"The study findings supporting this approval show that treatment with (Remicade) can slow the progression in joint destruction often associated with this disease," said Arthur Kavanaugh, professor of medicine at the University of California at San Diego.
- here's the UPI report on Remicade
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
